The Medical Letter on Drugs and Therapeutics
Fluticasone Furoate (Arnuity Ellipta) for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.1

MAINTENANCE TREATMENT — An inhaled corticosteroid is the most effective long-term treatment for control of mild, moderate, or severe persistent asthma. In randomized controlled trials, inhaled corticosteroids have been significantly more effective than long-acting beta2-agonists, leukotriene modifiers, cromolyn, or theophylline in improving pulmonary function, preventing symptoms and exacerbations, reducing the need for emergency department treatment, and decreasing deaths due to asthma. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluticasone Furoate (Arnuity Ellipta) for Asthma
Article code: 1469b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian